Harbor's Edge in Norfolk, VA

Harbor's Edge is a medicare certified nursing home in Norfolk, Virginia. It is located in Norfolk City county at One Colley Avenue, Norfolk, Virginia 23510. You can reach out to the office of Harbor's Edge via phone at (757) 233-0475. This skilled nursing facility has 33 federally certified beds with average occupancy rate of 70.61%. The nursing facility is classified as "Continuing Care Retirement Community" by CMS and its legal business name is Fort Norfolk Retirement Community, Inc. and has the following ownership type - Non Profit - Corporation.

Harbor's Edge (Medicare CCN 495395) is certified by CMS (Centers for Medicare & Medicaid Services) and participates in medicare program. This means if you are part of medicare program, you may consider this nursing facility for your medical needs. It was first certified by CMS in 2008 (16 years certified) and the last quality survey was conducted in September, 2019.

Name	Harbor's Edge
Location	One Colley Avenue, Norfolk, Virginia
Certified By	Medicare
No. of Certified Beds	33
Occupancy Rate	70.61%
Medicare ID (CCN)	495395
Legal Business Name	Fort Norfolk Retirement Community, Inc.
Ownership Type	Non Profit - Corporation

Nursing Homes may have multiple NPI numbers. We have found possible NPI number/s associated with Harbor's Edge from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.

NPI Number	1073600813
Organization Name	FORT NORFOLK RETIREMENT COMMUNITY, INC.
Doing Business As	HARBOR'S EDGE
Address	One Colley Ave, Norfolk, VA 23510
Phone Number	757-616-7900

News Archive

Adding therapy helps adolescents with depression not responding to SSRIs

For adolescents with depression not responding to an initial treatment with a selective serotonin reuptake inhibitor (SSRI; a class of antidepressant drugs), switching medications and adding cognitive behavioral therapy resulted in an improvement in symptoms, compared to just changing medications, according to a study in the February 27 issue of JAMA: The Journal of the American Medical Association.

Bayer submits an IND for its MN-IC antibody-drug conjugate to the FDA

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Bayer Schering Pharma AG, Germany. The milestone was triggered by Bayer's submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for MN-IC, an ADC for solid tumors.

Empathy and hormones could account for aggressive behavior in children, shows study

The research group in the Psychobiology section of the Department of Basic Psychological Processes and their Development of the UPV/EHU's Faculty of Psychology has spent many years studying aggressive behaviour in children.

Using artificial intelligence to help mitigate suicide risk

According to the CDC, the suicide rate for individuals 10-24 years old has increased 56% between 2007 and 2017.

Read more Medical News

› Verified 2 days ago

Nursing homes vary in the quality of care and services they provide to their residents. The below quality ratings for Harbor's Edge are calculated from three sources - health inspection results, staffing data, and quality measure data. This information gives you an indication of the care Harbor's Edge give to their patients.

Ratings from Surveys (Inspections):
Ratings from Quality Measures:
Ratings from Staffing Data:
Overall Rating:

News Archive

Adding therapy helps adolescents with depression not responding to SSRIs

For adolescents with depression not responding to an initial treatment with a selective serotonin reuptake inhibitor (SSRI; a class of antidepressant drugs), switching medications and adding cognitive behavioral therapy resulted in an improvement in symptoms, compared to just changing medications, according to a study in the February 27 issue of JAMA: The Journal of the American Medical Association.

Bayer submits an IND for its MN-IC antibody-drug conjugate to the FDA

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Bayer Schering Pharma AG, Germany. The milestone was triggered by Bayer's submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for MN-IC, an ADC for solid tumors.

Empathy and hormones could account for aggressive behavior in children, shows study

The research group in the Psychobiology section of the Department of Basic Psychological Processes and their Development of the UPV/EHU's Faculty of Psychology has spent many years studying aggressive behaviour in children.

Using artificial intelligence to help mitigate suicide risk

According to the CDC, the suicide rate for individuals 10-24 years old has increased 56% between 2007 and 2017.

Read more Medical News

› Verified 2 days ago

Number of Facility Reported Incidents	0
Number of Substantiated Complaints	0
Number of Fines	1
Total Amount of Fines in Dollars	$650
Number of Payment Denials	0
Total Number of Penalties	1

The resident survey data of Harbor's Edge is compared against the national average with the color code indicators: Better than National Average Worse than National Average

Experience Measure	Provider	National Avg.
Percentage of long-stay residents whose need for help with daily activities has increased	28.13	14.46
Percentage of long-stay residents who lose too much weight	30	5.51